All In Biotech

Drug Trial Radar · NCT07435129

Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the Efficacy and Safety of Apitegromab in Participants With Facioscapulohumeral Muscular Dystrophy (FORGE)

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Scholar Rock, Inc.Industry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD

Conditions

  • Facioscapulohumeral Muscular Dystrophy
  • FSHD

Interventions

  • ApitegromabDrug

    Apitegromab (SRK-015) is a fully human anti-promyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.

  • PlaceboDrug

    Placebo is administered every 4 weeks by intravenous (IV) infusion and does not contain the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the efficacy of apitegromab compared with placebo in participants with FSHDTime frame: 52 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Neuromuscular Research Institute

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.